ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMN ProMIS Neurosciences Inc

Trading 10-13 11:46:40 EDT

8.89

-0.56

-5.93%

High9.47	Low8.89	Vol13.98K
Open9.44	D1 Closing9.45	Amplitude6.14%
Mkt Cap79.72M	Tradable Cap39.02M	Total Shares8.97M
T/O130.16K	T/O Rate0.32%	Tradable Shares4.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMN","market":"US","secType":"STK","nameCN":"ProMIS Neurosciences Inc","latestPrice":8.89,"timestamp":1791906399583,"preClose":9.45,"halted":0,"volume":13978,"delay":0,"changeRate":-0.05925925925925913,"floatShares":4389100,"shares":8967700,"eps":-12.62,"marketStatus":"Trading","change":-0.56,"latestTime":"10-13 11:46:40 EDT","open":9.44,"high":9.47,"low":8.89,"amount":130163.820922,"amplitude":0.061376,"askPrice":9.23,"askSize":123,"bidPrice":8.89,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-12.62,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":9.45,"postHourTrading":{"tag":"盘后","latestPrice":9.36,"preClose":9.45,"latestTime":"19:30 EDT","volume":505,"amount":4727.37,"timestamp":1791847801936,"change":-0.09,"changeRate":-0.009524,"amplitude":0.009524},"volumeRatio":1.536644},"requestUrl":"/m/hq/s/PMN","defaultTab":"news","newsList":[{"id":"2673065422","title":"ProMIS Neurosciences Files Form 3 Initial Beneficial Ownership Statement for Chief Commercial Officer Ivana Rubino","url":"https://stock-news.laohu8.com/highlight/detail?id=2673065422","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673065422?lang=en_us&edition=fundamental","pubTime":"2026-10-07 05:04","pubTimestamp":1791320651,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences files Form 3 initial beneficial ownership statement for Chief Commercial Officer Ivana RubinoProMIS Neurosciences named Ivana Rubino as chief commercial officer in an initial Form 3 filing dated Oct. 5.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL73J9WS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673053790","title":"ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.d., as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673053790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673053790?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:05","pubTimestamp":1791284700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA900YB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672944717","title":"Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug","url":"https://stock-news.laohu8.com/highlight/detail?id=2672944717","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672944717?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:30","pubTimestamp":1790947800,"startTime":"0","endTime":"0","summary":"Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight advance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373844/0/en/climb-bio-to-present-new-data-at-american-society-of-nephrology-asn-kidney-week-2026-for-clym116-and-budoprutug.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0942090050.USD","BK4504","LU1074936037.SGD","LU1244550494.USD","LU0795875086.SGD","SLE","AFG","LU2347655156.SGD","PMN","LU0868494617.USD","LU0726765562.USD","BK4117","BK4107","PD","BK4218","LU1035773651.USD","LU1732800096.USD","MCD","LU0868494708.USD","LU1169590202.USD","LU1585245621.USD","LU0256863811.USD","LU1244550221.USD","LU1169589451.USD","BK4566","IE00B7KXQ091.USD","LU0795875169.SGD","LU1430594728.SGD","BK4209","IE00BJTD4V19.USD","IE00BJJMRY28.SGD","LU1069347547.HKD","BK4585","PK","LU0417517546.SGD","BK4181","LU2347655073.USD","BK4023","BK4139","BK4199","IE0004445015.USD","BK4610","BK4534","BK4550","BK4581","BK4588","IE00BJJMRX11.SGD","LU1732799900.SGD","ITP","KBWY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671420118","title":"ProMIS Neurosciences to Present at Chardan Annual Healthcare Conference Panel on Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2671420118","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671420118?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:06","pubTimestamp":1790769983,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences to present at Chardan annual healthcare conference panel on neurodegenerative diseasesProMIS Neurosciences to attend H.C. Wainwright Biotech On Tap 2026 in Munich on Sept. 30-Oct. 2.Neil Warma scheduled for the Lausanne XIII Annual Workshop in Lausanne on Oct. 6-8.Larry Altstiel to join a Chardan healthcare conference panel in New York on Tuesday, Oct. 20 at 2 p.m. ET.Company to participate in the Greater Boston Walk to End Alzheimer’s in Cambridge, Massachusetts on Sunday, Oct. 25.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL2Y7wvx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856415","title":"ProMIS Neurosciences to Present at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856415?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:03","pubTimestamp":1788264197,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences to present at Cantor Global Healthcare ConferenceProMIS Neurosciences will attend investor conferences in New York from Sept. 9-16, including Cantor Global Healthcare, Moody Capit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL3dJTh6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","CFSU","SG9999014005.SGD","NDAQ","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","LU2210150020.SGD","PMN","BK4585","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664562418","title":"ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2664562418","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664562418?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass, Sept.  01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354061/0/en/promis-neurosciences-to-participate-in-upcoming-conferences-and-events-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293350","title":"ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661293350?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:50","pubTimestamp":1787316650,"startTime":"0","endTime":"0","summary":"Roth Capital lowered the firm’s price target on ProMIS Neurosciences (PMN) to $29 from $30 and keeps a Buy rating on the shares. The company’s cent...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-price-target-lowered-to-29-from-30-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-price-target-lowered-to-29-from-30-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659142325","title":"ProMIS Neurosciences Price Target Raised to $100.00/Share from $69.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2659142325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659142325?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:39","pubTimestamp":1786714740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659475149","title":"Guggenheim Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659475149","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659475149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:18","pubTimestamp":1786709916,"startTime":"0","endTime":"0","summary":"In a report released today, Eddie Hickman from Guggenheim reiterated a Buy rating on ProMIS Neurosciences, with a price target of $100.00. Accordin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-promis-neurosciences-pmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-promis-neurosciences-pmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659966149","title":"Annovis Bio Q2 Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2659966149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659966149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:15","pubTimestamp":1786709731,"startTime":"0","endTime":"0","summary":"Annovis Bio Q2 loss widens as R&D costs riseOverviewUS biotech firm's Q2 net loss per share widened yr/yrCompany fully enrolled pivotal Phase 3 Alzheimer's trial, exceeding original targetQ2 research ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","PMN","CRMD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659419791","title":"Analysts Are Bullish on These Healthcare Stocks: ProMIS Neurosciences (PMN), Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659419791","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659419791?lang=en_us&edition=fundamental","pubTime":"2026-08-14 11:50","pubTimestamp":1786679406,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN) and Ascendis Pharma (ASND...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-promis-neurosciences-pmn-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-promis-neurosciences-pmn-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0889565916.HKD","ASND","BK4585","MEDI","PMN","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659116098","title":"ProMIS Neurosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659116098","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659116098?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:53","pubTimestamp":1786654425,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc reports results for the quarter ended June 30 - Earnings SummaryProMIS Neurosciences IncPMN.OQreported a quarterly adjusted loss of $1.28 per share for the quarter ended June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A27F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162415","title":"ProMIS Neurosciences Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162415","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162415?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651823,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Q2 net loss widensOverviewUS biotechnology firm's Q2 net loss widened yr/yrCash and short-term investments rose to $53.4 mln, funding operations through 2027Company reported posit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN","ABOS","ANNX","BK4539","MGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164089","title":"ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164089","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164089?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61191493/promis-neurosciences-q2-eps-1-28-beats-1-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164781","title":"ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164781?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:00","pubTimestamp":1786651200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUAJR6MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516009","title":"ProMIS Neurosciences Q2 EPS USD -1.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516009?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:00","pubTimestamp":1786651200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX52H5S9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658180059","title":"ProMIS Neurosciences Inc Expected to Post a Loss of $1.38 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658180059","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658180059?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:59","pubTimestamp":1786453148,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc <PMN.OQ> expected to post a loss of $1.38 a share - Earnings PreviewProMIS Neurosciences IncPMN.OQPMN.Ois expected to  show no change in quarterly revenue when it reports  res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44817H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625738","title":"ProMIS Neurosciences Chief Development Officer Johanne Kaplan Acquires 2,280 Common Shares Worth $30,324","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625738","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657625738?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:00","pubTimestamp":1786132858,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Chief Development Officer Johanne Kaplan acquires 2,280 common shares worth $30,324ProMIS Neurosciences Chief Development Officer Johanne Kaplan bought 2,280 common shares at USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL1zN4Dv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ProMIS Neurosciences Chief Development Officer Johanne Kaplan Acquires 2,280 Common Shares Worth $30,324","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656092103","title":"ProMIS Neurosciences to Report Q2 Results, Host Investor Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2656092103","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656092103?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:00","pubTimestamp":1785787215,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences to report Q2 results, host investor call and webcastProMIS Neurosciences will report Q2 results ended June 30, 2026 on Aug. 13, 2026.Investor conference call, webcast set for Aug.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3YtX5s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","SG9999014039.USD","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4585","BK4139","LU2210150020.SGD","BK4112","BCDF","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","PMN","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530784","title":"ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530784","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530784?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:00","pubTimestamp":1785787200,"startTime":"0","endTime":"0","summary":"Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug.  03, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337849/0/en/ProMIS-Neurosciences-to-Report-Second-Quarter-2026-Financial-Results-and-Business-Update-on-August-13-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.promisneurosciences.com","stockEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.3031},{"period":"3month","weight":-0.3082},{"period":"6month","weight":-0.2317},{"period":"1year","weight":-0.2286},{"period":"ytd","weight":0.3846}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.492325},{"month":2,"riseRate":0.5,"avgChangeRate":0.1186},{"month":3,"riseRate":0,"avgChangeRate":-0.161081},{"month":4,"riseRate":0.5,"avgChangeRate":0.06597},{"month":5,"riseRate":0,"avgChangeRate":-0.137867},{"month":6,"riseRate":0.25,"avgChangeRate":-0.061162},{"month":7,"riseRate":0.5,"avgChangeRate":0.083188},{"month":8,"riseRate":0,"avgChangeRate":-0.157931},{"month":9,"riseRate":0.4,"avgChangeRate":-0.072545},{"month":10,"riseRate":0.2,"avgChangeRate":-0.05966},{"month":11,"riseRate":0,"avgChangeRate":-0.242658},{"month":12,"riseRate":0.5,"avgChangeRate":-0.058437}],"exchange":"NASDAQ","name":"ProMIS Neurosciences Inc","nameEN":"ProMIS Neurosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProMIS Neurosciences Inc,PMN,ProMIS Neurosciences Inc股票,ProMIS Neurosciences Inc股票老虎,ProMIS Neurosciences Inc股票老虎国际,ProMIS Neurosciences Inc行情,ProMIS Neurosciences Inc股票行情,ProMIS Neurosciences Inc股价,ProMIS Neurosciences Inc股市,ProMIS Neurosciences Inc股票价格,ProMIS Neurosciences Inc股票交易,ProMIS Neurosciences Inc股票购买,ProMIS Neurosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction